相关实验视频

Updated: Jul 5, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

在细胞癌中指导免疫治疗的病理发现

Fadime Eda Gökalp Satıcı¹, Yasemin Yuyucu Karabulut²

¹Department of pathology, Tarsus State Hospital, Mersin, 33460, Turkey.

|January 12, 2024

概括

病理学在促进细胞癌 (RCC) 免疫治疗方面发挥着至关重要的作用. 本文探讨了病理学对开发和实施新型RCC免疫疗法的影响.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

免疫疗法彻底改变了癌症治疗,为患者提供了新的希望.
细胞癌 (RCC) 治疗格局正在迅速发展,随着新兴的免疫疗法选择.
了解病理学和免疫治疗之间的相互作用对于优化治疗策略至关重要.

研究的目的:

探索病理学在RCC免疫疗法开发中的多方面的作用.
调查病理洞察如何指导RCC免疫疗法的临床实施.
突出病理学在预测和监测RCC免疫治疗反应中的重要性.

主要方法:

关于免疫疗法和RCC病理学的当前文献的综述.
对免疫疗法疗效相关的病理生物标志物的分析.
案例研究示例,说明病理学在治疗决策中的作用.

主要成果:

病理学是确定可能从免疫治疗中受益的患者群体的组成部分.
通过病理学识别的组织病理学特征和分子标记物会影响治疗选择.
病理学有助于监测治疗反应和管理与免疫相关的不良事件.

结论:

病理学是成功开发和应用RCC免疫疗法的必不可少的.
整合先进的病理分析可以提高RCC免疫疗法的患者结果.
未来的研究应该集中在新的病理生物标志物上,以进一步完善RCC免疫疗法.

关键词:

免疫治疗是一种免疫疗法.在PD-1中使用PD-1.在PD-L1中.这就是尼沃卢马布 (nivolumab).细胞癌瘤是细胞癌.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.